Spanish Registry of Esophagogastric Cancer
AGAMENON
AGAMENON-SEOM Study: Spanish Registry of Esophagogastric Cancer
2 other identifiers
observational
10,000
1 country
38
Brief Summary
This study aims to development of a database through a web page for epidemiological and clinical research purposes that is accessible to members of the AGAMENON - SEOM group that guarantees a rigorous collection, exploitation and analysis of the data and information contained, increases the knowledge of esophageal and stomach cancer in order to optimize the management, treatment and evolution of patients, the possibility of comparing variables with those of other series or groups, and promotes the quality of scientific publications.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Apr 2020
Longer than P75 for all trials
38 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
April 27, 2020
CompletedFirst Submitted
Initial submission to the registry
June 14, 2021
CompletedFirst Posted
Study publicly available on registry
July 12, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2034
ExpectedStudy Completion
Last participant's last visit for all outcomes
December 1, 2035
July 3, 2025
June 1, 2025
14.6 years
June 14, 2021
June 30, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Diagnostic and therapeutic approach
To evaluate survival (time in months) according to treatment of esophagogastric cancer in all stages, patients, and contexts.
Up to 12 months
Secondary Outcomes (8)
Epidemiological profiles
Up to 12 months
Risk factors
Up to 12 months
Pathological features
Up to 12 months
Clinical and diagnostic approach
Up to 12 months
Treatments adjusted to prognostic variables
Up to 12 months
- +3 more secondary outcomes
Study Arms (2)
Cohort 1
Resectable non-advanced cancer
Cohort 2
Unresectable advanced cancer
Interventions
Chemotherapy, anti-targeted agents and immunotherapy
Eligibility Criteria
The study plans to enroll patients with histologically confirmed carcinoma of the esophagus, gastroesophageal junction, and stomach. The inclusion of patients is required to be done consecutively, being valid any time point if data are available.
You may qualify if:
- Adult patient (≥18 years) diagnosed with carcinoma of the esophagus, gastroesophageal junction and stomach, including all histologic subtypes, with or without erbB2 overexpression (and tumors in which this data is unknown).
- Follow-up of at least 3 months with clinical information during this period, exempting patients with early death from any cause.
You may not qualify if:
- A patient for whom, for whatever reason, the information necessary to complete the database cannot be known or obtained.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (38)
Hospital General Universitario de Alicante
Alicante, Alicante, 03010, Spain
Hospital General Universitario de Elche
Elche, Alicante, 03203, Spain
Hospital General Universitario de Elda
Elda, Alicante, 03600, Spain
Hospital Universitario Reina Sofia
Córdoba, Andalusia, 14004, Spain
Hospital Regional Universitario de Málaga
Málaga, Andalusia, 29010, Spain
Hospital Universitario Virgen Macarena
Seville, Andalusia, 41009, Spain
Hospital Universitario Virgen del Rocio
Seville, Andalusia, 41013, Spain
Hospital Universitario Son Espases
Palma de Mallorca, Balearic Islands, 07120, Spain
Hospital Son Llàtzer
Palma de Mallorca, Balearic Islands, 07198, Spain
Hospital del Mar
Barcelona, Barcelona, 08003, Spain
Hospital Universitario Vall d'Hebrón
Barcelona, Barcelona, 08035, Spain
Hospital Clínic de Barcelona
Barcelona, Barcelona, 08036, Spain
Hospital de la Santa Creu i Sant Pau
Barcelona, Barcelona, 08041, Spain
Institut Català d'Oncologia
L'Hospitalet de Llobregat, Barcelona, 08908, Spain
Hospital Universitari Parc Taulí
Sabadell, Barcelona, 08208, Spain
Hospital Universitario Marques de Valdecillas
Santander, Cantabria, 39008, Spain
Hospital General Universitario de Ciudad Real
Ciudad Real, Ciudad Real, 13005, Spain
Hospital Universitario de Jaén
Jaén, Jaén, 23007, Spain
Complejo Hospitalario Universitario de A Coruña
A Coruña, La Coruña, 15006, Spain
Hospital San Pedro
Logroño, La Rioja, 26006, Spain
Hospital Universitario Fundación Alcorcón
Alcorcón, Madrid, 28922, Spain
Hospital General Universitario Gregorio Marañón
Madrid, Madrid, 28007, Spain
Hospital Universitario Ramón y Cajal
Madrid, Madrid, 28034, Spain
Hospital Clínico San Carlos
Madrid, Madrid, 28040, Spain
Hospital Universitario 12 de Octubre
Madrid, Madrid, 28041, Spain
Hospital Universitario La Paz
Madrid, Madrid, 28046, Spain
Hospital Central de la Defensa Gómez Ulla
Madrid, Madrid, 28047, Spain
Hospital General Universitario Santa Lucía
Cartagena, Murcia, 30202, Spain
Hospital General Universitario Morales Meseguer
Murcia, Murcia, 30008, Spain
Complejo Hospitalario Universitario de Ourense
Ourense, Ourense, 32005, Spain
Hospital Universitario de Navarra
Pamplona, Pamplona, 31008, Spain
Hospital Provincial de Pontevedra
Pontevedra, Pontevedra, 36002, Spain
Hospital Universitario Central de Asturias
Oviedo, Principality of Asturias, 33011, Spain
Complejo Asistencial Universitario de Salamanca
Salamanca, Salamanca, 37007, Spain
Hospital Universitario de Canarias
San Cristóbal de La Laguna, Santa Cruz de Tenerife, 38320, Spain
Hospital Universitario Nuestra Señora de la Candelaria
Santa Cruz de Tenerife, Santa Cruz de Tenerife, 38010, Spain
Hospital General Universitario de Valencia
Valencia, Valencia, 46014, Spain
Hospital Universitario de Galdakao
Galdakao, Vizcaya, 48960, Spain
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Paula Dr Jiménez Fonseca, MD-PhD
Sociedad Española de Oncología Medica (SEOM)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
June 14, 2021
First Posted
July 12, 2021
Study Start
April 27, 2020
Primary Completion (Estimated)
December 1, 2034
Study Completion (Estimated)
December 1, 2035
Last Updated
July 3, 2025
Record last verified: 2025-06
Data Sharing
- IPD Sharing
- Will not share